Caixa Capital Risk invests in Inbiomotion
10/03/2016
Diego Gutiérrez
Caixa Capital Risk invests in Inbiomotion
It seems that biotechnology is finding investors in our country. A few weeks ago we told you that Inveready had invested in Cuantum and Ab-biotics, this week we learned that Oncostellae, which received a €1M round is looking for funding, and Caixa Capital Risk has led a €2.2M round in Inbiomotion.

la Caixa's investment in Inbiomotion

La Caixa, through Caixa Innvierte BioMed II, has led a €2.2M round of funding in Inbiomotion, a spin-off of the Barcelona Biomedical Research Institute that develops diagnostic tests to predict the risk of cancer patients suffering from bone metastasis.

Also participating in the round were Ysios Capitalthe leading Spanish investment manager in the biotechnology sector, through its Ysios BioFund I, and the Vila Casas Foundation, which were already shareholders of the company.

This round will complete the clinical validation and make Inbiomotion's first product available to patients.

Inbiomotion's product, Osteomet, has already been validated in more than 1,300 patient samples from independent, multi-country cohorts and the company's primary goal is to complete its clinical and regulatory development within the next 2 years.

La Caixa is committed to biotechnology and creates Caixa Innvierte Start.

It is also in the news that last December the Caixa registered a new fund for technology SMEs with the CNMV, mainly for companies in the health and biotechnology sectors, although other sectors are not ruled out.

 La Caixa will focus on Spanish start-ups (although it does not rule out the "exceptional" possibility of making purchases in other geographies as long as they do not consume 20% of the total resources raised by the fund) and with an outstanding potential for innovation and growth.

These general guidelines are quite favourable for the new fund to receive the injection of the government's fund of funds articulated through the ICO, Fond-ICO Global -whose sixth call remains open until 29 March. In fact, in the management regulations that Caixa Innvierte Start has submitted to the CNMV, there is a specific article (article 17) that regulates the intervention of public participants.

If you are looking for financing, please contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Call + 34 946424142 or fill in the contact form.

Other posts that may interest you

Inveready bets on biotechnology, invests in Cuantum and AB-Biotics in less than a month

Investors lose their fear of investing in biotechnology

Biotech operations: Minoryx, Suanfarma, Ability Pharma and Oryzon Genomics

Lastest news

Últimas transacciones del sector Cybersecurity

El sector de la ciberseguridad ha sido testigo de una importante oleada de adquisiciones estratégicas en los últimos meses, a medida que las empresas tratan de ampliar sus capacidades y hacer frente a la creciente demanda de una sólida protección digital. Cinco...

Latest transactions in the Consumer Software sector

El sector del Consumer software ha experimentado recientemente una dinámica oleada de adquisiciones que pone de relieve su evolución hacia la mejora de la participación de los usuarios y la ampliación de los servicios digitales. Entre las operaciones más destacadas...

Latest transactions in the Industrial Tech sector

El sector de la tecnología industrial ha sido testigo de una oleada de transacciones estratégicas en los últimos meses, señal de una rápida evolución y expansión. Entre las operaciones más destacadas, Bosch Energy and Building Solutions adquirió DMS Ettlingen para...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

Request for information

If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

Or if you prefer, call us at:

+34 946 42 41 42